Scientist Synthesizes New Molecule That Kills Hard-To-Treat Breast Cancer
Dr. Jung-Mo Ahn led a team of researchers in the creation of ERX-41, a new compound that uses breast cancer cells’ own weaknesses to “wipe out” tumor cells. Most existing breast cancer treatments require the presence of estrogen receptors (ERs) to work. This leaves few options for patients with triple-negative breast cancer, or TNBC, which lacks ERs and therefore is resistant to such treatments.
Meanwhile, ERX-41 is effective regardless of whether the targeted cancer cells possess ERs. It works by binding with lysosomal acid lipase A (LIPA), a protein found in the cell’s endoplasmic reticulum. (You might remember this as the maze-like cellular structure on all your middle school biology exams.) Cancer cells produce far more LIPA than necessary, but the endoplasmic reticulum usually processes them efficiently enough to keep the cells healthy. When ERX-41 binds to LIPA, however, it jams the endoplasmic reticulum and causes a buildup, which eventually bloats and kills the cell.
Dr. Ahn’s team tested ERX-41 in isolated cells and human cancer tissue, where the molecule inhibited growth without killing healthy cells. They then tested the molecule in live mice with various forms of human cancer. ERX-41 successfully reduced the size of their tumors without producing any adverse effects, such as weight fluctuation or behavioral changes. (A later test in healthy mice further solidified a lack of negative side effects.) The molecule’s effectiveness with other treatment-resistant cancers, like pancreatic cancer, ovarian cancer, and glioblastoma, led the researchers to believe ERX-41 might someday be used to treat those diseases as well.
This isn’t the first time Dr. Ahn has moved the needle in regards to beating treatment-resistant cancers. Less than five years ago he developed candidate compounds that block the co-regulators necessary for breast cancer to grow. A few years before that, Dr. Ahn synthesized another molecule capable of inhibiting the growth of prostate cancer.
Dr. Ahn and two colleagues founded EtiraRX, a Dallas therapeutics startup, in order to conduct clinical trials of each novel treatment. Patents are currently pending for ERX-41; in the meantime, the team is busy planning clinical trials for ERX-41, which will begin in early 2023.
Continue reading
NASA Discovers Vital Organic Molecule on Titan
In the latest analysis, researchers from NASA have identified an important, highly reactive organic molecule in Titan's atmosphere. Its presence suggests the moon could support chemical processes that we usually associate with life.
Scientists Discover Molecule That Can Fight Drug-Resistant Bacteria
A team of chemists and molecular biologists appear to have found the key to fighting drug resistance, and it’s hidden in a molecule called fabimycin.
Organic Molecules on Ceres Are More Abundant Than Previously Thought
New research suggests there may be higher concentration of organic molecules on Ceres than originally believed. Where'd they come from? That's a major question.
NASA Detects Universe’s Earliest Molecule for the First Time
Scientists have long suspected that helium hydride was the first molecule in the universe, but no one has ever detected it in space until now. NASA researchers have spotted helium hydride many light years away in a planetary nebula.